Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Raw Materials: 2022-2024

Historic Raw Materials for Gyre Therapeutics (GYRE) over the last 3 years, with Dec 2024 value amounting to $794,000.

  • Gyre Therapeutics' Raw Materials rose 5.77% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 5.77%. This contributed to the annual value of $794,000 for FY2024, which is 13.60% down from last year.
  • Gyre Therapeutics' Raw Materials amounted to $794,000 in FY2024, which was down 13.60% from $919,000 recorded in FY2023.
  • In the past 5 years, Gyre Therapeutics' Raw Materials registered a high of $1.1 million during FY2022, and its lowest value of $794,000 during FY2024.
  • Over the past 3 years, Gyre Therapeutics' median Raw Materials value was $919,000 (recorded in 2023), while the average stood at $923,000.
  • Data for Gyre Therapeutics' Raw Materials shows a maximum YoY fell of 13.60% (in 2024) over the last 5 years.
  • Gyre Therapeutics' Raw Materials (Yearly) stood at $1.1 million in 2022, then fell by 12.97% to $919,000 in 2023, then declined by 13.60% to $794,000 in 2024.